A Phase II, Open Label, Single Arm Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) as a Single Agent in a Cohort of HIV Positive Adult Patients.
Phase of Trial: Phase II
Latest Information Update: 03 May 2017
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 27 Apr 2017 Status changed from recruiting to completed.
- 03 Apr 2009 New trial record